Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries
BackgroundRectal cancer has a high risk of recurrence and metastasis, with median survival ranging from 24 months to 36 months. K-RAS mutation is a predictor of poor prognosis in rectal cancer. Advanced rectal cancer can be stopped in its tracks by pelvic exenteration.Case summaryA 51-year-old woman...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1169616/full |
| _version_ | 1797826810757513216 |
|---|---|
| author | Ye Ouyang Yilin Zhu Haoyi Chen Guoquan Li Xiongwei Hu Hongyu Luo Zhou Li Shuai Han |
| author_facet | Ye Ouyang Yilin Zhu Haoyi Chen Guoquan Li Xiongwei Hu Hongyu Luo Zhou Li Shuai Han |
| author_sort | Ye Ouyang |
| collection | DOAJ |
| description | BackgroundRectal cancer has a high risk of recurrence and metastasis, with median survival ranging from 24 months to 36 months. K-RAS mutation is a predictor of poor prognosis in rectal cancer. Advanced rectal cancer can be stopped in its tracks by pelvic exenteration.Case summaryA 51-year-old woman was diagnosed with advanced rectal cancer (pT4bN2aM1b, stage IV) with the KRAS G12D mutation due to a change in bowel habits. The patient had experienced repeated recurrences of rectal cancer after initial radical resection, and the tumor had invaded the ovaries, sacrum, bladder, vagina and anus. Since the onset of the disease, the patient had undergone a total of seven surgeries and long-term FOLFIRI- or XELOX-based chemotherapy regimens, with the targeted agents bevacizumab and regorafenib. Fortunately, the patient was able to achieve intraoperative R0 resection in almost all surgical procedures and achieve tumor-free survival after pelvic exenteration. The patient has been alive for 86 months since her diagnosis.ConclusionsPatients with advanced rectal cancer can achieve long-term survival through active multidisciplinary management and R0 surgery. |
| first_indexed | 2024-04-09T12:38:13Z |
| format | Article |
| id | doaj.art-061f2df0eb714419aaa2fdbfac41d556 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T12:38:13Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-061f2df0eb714419aaa2fdbfac41d5562023-05-15T04:59:37ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-05-011310.3389/fonc.2023.11696161169616Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeriesYe Ouyang0Yilin Zhu1Haoyi Chen2Guoquan Li3Xiongwei Hu4Hongyu Luo5Zhou Li6Shuai Han7The Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, ChinaDepartment of General Surgery, Guangdong Province Huizhou Sixth Hospital, Huizhou, ChinaDepartment of General Surgery, Guangdong Province Huizhou Sixth Hospital, Huizhou, ChinaDepartment of General Surgery, Guangdong Province Huizhou Sixth Hospital, Huizhou, ChinaDepartment of Gastrointestinal Surgery, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, ChinaBackgroundRectal cancer has a high risk of recurrence and metastasis, with median survival ranging from 24 months to 36 months. K-RAS mutation is a predictor of poor prognosis in rectal cancer. Advanced rectal cancer can be stopped in its tracks by pelvic exenteration.Case summaryA 51-year-old woman was diagnosed with advanced rectal cancer (pT4bN2aM1b, stage IV) with the KRAS G12D mutation due to a change in bowel habits. The patient had experienced repeated recurrences of rectal cancer after initial radical resection, and the tumor had invaded the ovaries, sacrum, bladder, vagina and anus. Since the onset of the disease, the patient had undergone a total of seven surgeries and long-term FOLFIRI- or XELOX-based chemotherapy regimens, with the targeted agents bevacizumab and regorafenib. Fortunately, the patient was able to achieve intraoperative R0 resection in almost all surgical procedures and achieve tumor-free survival after pelvic exenteration. The patient has been alive for 86 months since her diagnosis.ConclusionsPatients with advanced rectal cancer can achieve long-term survival through active multidisciplinary management and R0 surgery.https://www.frontiersin.org/articles/10.3389/fonc.2023.1169616/fullrectal cancerrecurrencepelvic exenterationlong-term survivalKRAS mutation |
| spellingShingle | Ye Ouyang Yilin Zhu Haoyi Chen Guoquan Li Xiongwei Hu Hongyu Luo Zhou Li Shuai Han Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries Frontiers in Oncology rectal cancer recurrence pelvic exenteration long-term survival KRAS mutation |
| title | Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries |
| title_full | Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries |
| title_fullStr | Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries |
| title_full_unstemmed | Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries |
| title_short | Case Report: Long-term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries |
| title_sort | case report long term survival of a patient with advanced rectal cancer and multiple pelvic recurrences after seven surgeries |
| topic | rectal cancer recurrence pelvic exenteration long-term survival KRAS mutation |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1169616/full |
| work_keys_str_mv | AT yeouyang casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries AT yilinzhu casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries AT haoyichen casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries AT guoquanli casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries AT xiongweihu casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries AT hongyuluo casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries AT zhouli casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries AT shuaihan casereportlongtermsurvivalofapatientwithadvancedrectalcancerandmultiplepelvicrecurrencesaftersevensurgeries |